Detalhes bibliográficos
Ano de defesa: |
2012 |
Autor(a) principal: |
Brum, Charles Ornelas
 |
Orientador(a): |
Pitrez, Paulo Márcio Condessa
 |
Banca de defesa: |
Não Informado pela instituição |
Tipo de documento: |
Tese
|
Tipo de acesso: |
Acesso aberto |
Idioma: |
por |
Instituição de defesa: |
Pontifícia Universidade Católica do Rio Grande do Sul
|
Programa de Pós-Graduação: |
Programa de Pós-Graduação em Medicina/Pediatria e Saúde da Criança
|
Departamento: |
Faculdade de Medicina
|
País: |
BR
|
Palavras-chave em Português: |
|
Área do conhecimento CNPq: |
|
Link de acesso: |
http://tede2.pucrs.br/tede2/handle/tede/1386
|
Resumo: |
Sepsis is a systemic inflammatory disorder, and its progression to septic shock is a serious clinical problem associated with a high mortality rate. Despite significant advances in critical care, treatments do not reverse the systemic inflammatory response and its consequences. Gram-negative sepsis is initiated by exposure to a component of gram-negative bacterial membrane, lipopolysaccharide (LPS), and induces overproduction of host inflammatory cytokines, including tumor necrosis factor (TNF- α), interleukin-1 (IL-1) and interleukin-6 (IL-6) from immunocytes such as monocytes. Recent studies have shown that similar to LPS, the Respiratory syncytial virus - leading cause of severe lower respiratory tract infections in infants and young children requires the toll-like receptor 4 (TLR4) for signaling. Studies have shown that the respiratory syncytial virus attachment glycoprotein (RSV G) modulates cytokine and chemokine production in monocytes, inhibiting the inflammatory response elicited by LPS stimulation. In this report, we use murine monocytes from different knockout mice to show that RSV G can inhibit the release of cytokines in the immune response against lipoplysaccharide induced sepsis. We demonstrate the modulation of IL-1β, IL-6, IL-10 and TNF-α by RSV G in monocytes LPS stimulated. Importantly, we also considered the effect of RSV G subunits (peptides) and future directions for the clinical use of the glycoprotein on LPS-mediated inflammation. |